Award-winning salon owner, educator & industry consultant, Theresa Foddering, aka The Naildresser , explains the difference ...

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in common that they are triggered by an excessive immune response -- which in ...

On Tuesday morning, Galderma launched its Scratch Resistance campaign to highlight one of the most difficult symptoms of atopic dermatitis: nonstop itching. The campaign’s ad spot features atopic ...

DELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and investigational delgocitinib topical treatment for Chronic Hand Eczema (CHE).1 ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

The FDA has approved Dupixent for chronic spontaneous urticaria in patients 12 and older unresponsive to antihistamines, ...

Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification ...

Held in partnership with HCPLive® and Dermatology Times®, RAD 2025 is designed to arm dermatologists and other health care ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous ...